Contribution of Pharmacoeconomics to Enhancing the Pharmaceutical Industry Development
The culture of evidence-based healthcare, quality-linked incentives, and patient-centered actions, driven by the natural financial constraints on health systems budgets, led to a growing interest by decision and policymakers in expanding Health Technology Assessment (HTA) criteria to Pricing and Reimbursement (P&R) of a given technology (e.g., drug, vaccine, procedure, service), especially in disease areas with […]
